Long-term cardiac safety of dose-dense anthracycline therapy cannot be predicted from early ejection fraction data

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6073-6075

  Ewer, Michael S ^a   Ewer, Steven M ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRACYCLINE;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG SAFETY; EDITORIAL; HEART EJECTION FRACTION; HUMAN; PREDICTION; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; NOTE; PREDICTION AND FORECASTING;

ANTHRACYCLINES; CARDIAC ELECTROPHYSIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART DISEASES; HUMANS; PREDICTIVE VALUE OF TESTS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 74949132781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.5091     Document Type: Editorial

References (8)

1. Morris PG, Dickler M, McArthur HL, et al: Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 27:6117-6123, 2009
2. Ewer M, Ali M, Mackay B, et al: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 2:112-117, 1984
3. Cardinale A, Sandri M, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002
4. Ewer M, Benjamin R: Formulae for predicting the likelihood of developing congestive heart failure following anthracycline chemotherapy: Added evidence for early cardiotoxicity. Journal of Cardiac Failure 11:S159, 2005 (suppl; abstr 259)
5. Gottlieb SL, Edmiston WA Jr, Haywood LJ: Late, late doxorubicin cardiotoxicity. Chest Dec 78:880-882, 1980
6. Legha S, Benjamin R, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982
7. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003
8. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B31. J Clin Oncol 23:7811-7819, 2005